Thomas J Ford

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9100747/publications.pdf

Version: 2024-02-01

73 papers 2,609 citations

279798
23
h-index

189892 50 g-index

79 all docs

79 docs citations

79 times ranked 2983 citing authors

#	Article	IF	CITATIONS
1	Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina. Journal of the American College of Cardiology, 2018, 72, 2841-2855.	2.8	436
2	Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. New England Journal of Medicine, 2018, 378, 603-614.	27.0	399
3	1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA). JACC: Cardiovascular Interventions, 2020, 13, 33-45.	2.9	141
4	Systemic microvascular dysfunction in microvascular and vasospastic angina. European Heart Journal, 2018, 39, 4086-4097.	2.2	139
5	Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2021, 6, 1130.	6.1	114
6	Ischemia and No Obstructive Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2019, 12, e008126.	3.9	107
7	Assessment of Vascular Dysfunction inÂPatients Without Obstructive CoronaryÂArtery Disease. JACC: Cardiovascular Interventions, 2020, 13, 1847-1864.	2.9	105
8	Pharmacodynamic effects of a novel prokinetic 5-HT4receptor agonist, ATI-7505, in humans. Neurogastroenterology and Motility, 2007, 19, 30-38.	3.0	101
9	Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2019, 321, 56.	7.4	88
10	Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need. Heart, 2018, 104, 284-292.	2.9	86
11	Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group. European Heart Journal, 2021, 42, 4592-4600.	2.2	84
12	Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR). European Heart Journal, 2021, 42, 4656-4668.	2.2	79
13	Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction. European Heart Journal, 2020, 41, 3239-3252.	2.2	73
14	Smallâ€Vessel Disease in the Heart and Brain: Current Knowledge, Unmet Therapeutic Need, and Future Directions. Journal of the American Heart Association, 2019, 8, e011104.	3.7	71
15	Single―Versus 2‧tent Strategies for Coronary Bifurcation Lesions: A Systematic Review and Metaâ€Analysis of Randomized Trials With Longâ€Term Followâ€up. Journal of the American Heart Association, 2018, 7, .	3.7	53
16	How to Diagnose and Manage Angina Without Obstructive Coronary Artery Disease: Lessons from the British Heart Foundation CorMicA Trial. Interventional Cardiology Review, 2019, 14, 76-82.	1.6	50
17	Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial. American Heart Journal, 2020, 229, 70-80.	2.7	40
18	Advances in computational modelling for personalised medicine after myocardial infarction. Heart, 2018, 104, 550-557.	2.9	39

#	Article	IF	CITATIONS
19	Physiological Predictors of AcuteÂCoronaryÂSyndromes. JACC: Cardiovascular Interventions, 2017, 10, 2539-2547.	2.9	38
20	Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial. Thrombosis and Haemostasis, 2019, 119, 1171-1181.	3.4	31
21	Angina: contemporary diagnosis and management. Heart, 2020, 106, 387-398.	2.9	29
22	Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Function and CT Coronary Angiogram (CorCTCA) study. American Heart Journal, 2020, 221, 48-59.	2.7	27
23	Minocycline hepatitis. European Journal of Gastroenterology and Hepatology, 2008, 20, 796-799.	1.6	26
24	Sex differences in procedural and clinical outcomes following rotational atherectomy. Catheterization and Cardiovascular Interventions, 2020, 95, 232-241.	1.7	24
25	Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. American Heart Journal, 2018, 201, 86-94.	2.7	22
26	Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time. Journal of the American College of Cardiology, 2020, 75, 1406-1421.	2.8	16
27	Ankyrin-B Syndrome: A Case of Sinus Node Dysfunction, Atrial Fibrillation and Prolonged QT in a Young Adult. Heart Lung and Circulation, 2015, 24, e31-e34.	0.4	14
28	Selective anti-scatter grid removal during coronary angiography and PCI: a simple and safe technique for radiation reduction. International Journal of Cardiovascular Imaging, 2017, 33, 771-778.	1. 5	13
29	Percutaneous coronary intervention versus medical therapy in patients with angina and grey-zone fractional flow reserve values: a randomised clinical trial. Heart, 2020, 106, 758-764.	2.9	13
30	Rationale and design of the Coronary Microvascular Angina Cardiac Magnetic Resonance Imaging (CorCMR) diagnostic study: the CorMicA CMR sub-study. Open Heart, 2018, 5, e000924.	2.3	12
31	Coronary Microvascular Dysfunction. Journal of the American College of Cardiology, 2018, 72, 584-586.	2.8	11
32	Stratified medicine using invasive coronary function testing in angina: A cost-effectiveness analysis of the British Heart Foundation CorMicA trial. International Journal of Cardiology, 2021, 337, 44-51.	1.7	11
33	Coronary artery disease: physiology and prognosis. European Heart Journal, 2017, 38, 1990-1992.	2.2	10
34	Balloon Aortic Valvuloplasty in the Transcatheter Valve Era: Single Centre Indications and Early Safety Data in a High Risk Population. Heart Lung and Circulation, 2018, 27, 595-600.	0.4	8
35	Ultrathin-strut biodegradable polymer versus durable polymer drug-eluting stents: a meta-analysis. Open Heart, 2020, 7, e001394.	2.3	8
36	Risk Stratification Guided by the Index of Microcirculatory Resistance and Left Ventricular End-Diastolic Pressure in Acute Myocardial Infarction. Circulation: Cardiovascular Interventions, 2021, 14, e009529.	3.9	8

#	Article	IF	Citations
37	Incidence of Acute Bronchospasm during Systemic Adenosine Administration for Coronary Angiography. Journal of the Royal College of Physicians of Edinburgh, The, 2019, 49, 204-206.	0.6	8
38	Bias and Loss to Followâ€Up in Cardiovascular Randomized Trials: A Systematic Review. Journal of the American Heart Association, 2020, 9, e015361.	3.7	7
39	Cessation of dual antiplatelet therapy and cardiovascular events following acute coronary syndrome. Heart, 2019, 105, 67-74.	2.9	6
40	International prospective cohort study of microvascular angina – Rationale and design. IJC Heart and Vasculature, 2020, 31, 100630.	1.1	6
41	Pulmonary hypertension and hepatic encephalopathy: lethal complications of Rendu-Osler-Weber disease. Journal of the Royal College of Physicians of Edinburgh, The, 2014, 44, 126-129.	0.6	5
42	One-Year Outcomes After Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008855.	3.9	5
43	Post-operative myocardial infarction following aortic root surgery with coronary reimplantation: a case series treated with percutaneous coronary intervention. European Heart Journal - Case Reports, 2019, 3, 1-6.	0.6	4
44	Rapid Dissemination of Protocols for Managing Neurology Inpatients with ⟨scp⟩COVID⟨/scp⟩â€19. Annals of Neurology, 2020, 88, 211-214.	5.3	4
45	Revascularisation and mechanical circulatory support in patients with ischaemic cardiogenic shock. Heart, 2019, 105, 1364-1374.	2.9	3
46	MINOCA: Requirement for Definitive Diagnostic Work-Up. Heart Lung and Circulation, 2019, 28, e4-e6.	0.4	3
47	Proteasome inhibitor-induced coronary vasospasm in multiple myeloma: a case report. European Heart Journal - Case Reports, 2021, 5, ytab076.	0.6	3
48	Comparative study of costs and resource utilisation of rotational atherectomy versus intravascular lithotripsy for percutaneous coronary intervention. Minerva Cardiology and Angiology, 2021, , .	0.7	3
49	Arterial Access for Invasive Coronary Angiography: The â€~Left Backhander'. Heart Lung and Circulation, 2018, 27, e98-e99.	0.4	2
50	Scientific Business Abstracts of the 113th Annual Meeting of the Association of Physicians of Great Britain and Ireland. QJM - Monthly Journal of the Association of Physicians, 2019, 112, 724-729.	0.5	1
51	"Vessels of Vessels― JACC: Cardiovascular Interventions, 2021, 14, 619-622.	2.9	1
52	Neurologic Emergencies during the Coronavirus Disease 2019 Pandemic. Neurologic Clinics, 2021, 39, 671-687.	1.8	1
53	Investigating the efficacy of chest pressure for direct current cardioversion in atrial fibrillation: a randomised control trial protocol (Pressure-AF). Open Heart, 2021, 8, e001739.	2.3	1
54	An ECG that changed in a febrile patient. BMJ, The, 2013, 346, f585-f585.	6.0	0

#	Article	IF	Citations
55	Patent ductus arteriosus illuminating an old eponym. BMJ, The, 2016, 353, i2182.	6.0	O
56	Coronary physiology and prognosis – What does pressure-bounded coronary flow reserve add?. International Journal of Cardiology, 2018, 261, 32-34.	1.7	0
57	TCT-405 Sex Differences and Outcomes Following Rotational Atherectomy: Do Women Receive Optimal Care?. Journal of the American College of Cardiology, 2018, 72, B163-B164.	2.8	0
58	TCT-185 Glasgow Rotational Atherectomy Efficiency (GRACE) study: Safety of a Minimalist Approach. Journal of the American College of Cardiology, 2018, 72, B79.	2.8	0
59	Strategies in Stable Chronic Coronary Disease. , 2018, , 901-919.		0
60	A keen eye for risk. BMJ: British Medical Journal, 2018, 360, j5884.	2.3	0
61	$16 \hat{a} \in$ Cangrelor versus ticagrelor in primary percutaneous coronary intervention: platelets, microcirculation and infarct size. , 2018, , .		0
62	TCT-28 Comparative Study of Resource Utilization, Costs, and Procedural Times of Percutaneous Coronary Intervention With Rotational Atherectomy Versus Intravascular Lithotripsy. Journal of the American College of Cardiology, 2019, 74, B28.	2.8	0
63	TCT-591 A Comparison of Clinical and Coronary Physiology Characteristics in Patients With and Without Type 4a Myocardial Infarction Following High Speed Rotational Atherectomy–Assisted Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2019, 74, B582.	2.8	0
64	TCT-678 Long-Term Outcomes of Revascularization Post Coronary Artery Bypass Surgery. Journal of the American College of Cardiology, 2019, 74, B665.	2.8	0
65	50 $\hat{a} \in$ Is chaemia and No Obstructive Coronary Artery Disease (INOCA): prevalence and predictors of coronary vasomotion disorders. , 2019, , .		0
66	Chest pain with a cold. BMJ, The, 2020, 371, m3742.	6.0	0
67	EMG Analysis Of Muscle Firing Patterns At The Shoulder And Elbow During The Volleyball Serve. Medicine and Science in Sports and Exercise, 2005, 37, S120-S121.	0.4	0
68	Stable Coronary Syndromes. , 2019, , 373-381.		0
69	Intravenous cangrelor vs oral ticagrelor in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous intervention: A randomised controlled trial. Clinical Medicine, 2019, 19, s128-s128.	1.9	0
70	Abstract 089: Role of Nox5 in Systemic Vascular Dysfunction in Ischemic Heart Disease. Hypertension, 2019, 74, .	2.7	0
71	3 Rationale and design of the Medical Research Council Precision medicine with Zibotentan in microvascular angina (PRIZE) trial MRI sub-study. , 2021, , .		0
72	Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-86.	0.7	0

THOMAS J FORD

#	Article	IF	CITATIONS
73	Acetylcholine (Re)challenge. JACC: Cardiovascular Interventions, 2022, 15, 76-79.	2.9	O